Raphael Pharmaceutical RAPH Income Statement (2020-2026)

OTC RAPH
$1.40 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

Raphael Pharmaceutical Quarterly Income Statement

Periods 22 quarters
Latest Jun 2026

Raphael Pharmaceutical reported net income of -$0.22M for the quarter ended Jun 2026. This income statement covers 22 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating items
Research & DevelopmentR&D
0.22M0.16M0.22M0.09M0.08M0.33M0.68M0.11M0.29M0.51M-0.35M0.38M0.02M0.16M0.21M0.14M0.04M
Selling, General & AdministrativeSG&A
0.16M0.26M0.35M0.09M0.53M1.09M0.43M0.14M0.13M0.22M0.27M0.17M0.23M0.16M0.18M0.17M0.16M
Operating ExpensesOpex
0.39M0.42M0.57M0.17M0.61M1.43M1.10M0.26M0.42M0.73M-0.07M0.55M0.25M0.32M0.39M0.32M0.20M
Operating IncomeOp. Inc
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
EBIT
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
Non-operating items
Non Operating IncomeNon Op. Inc.
-0.00M0.00M0.01M-0.01M-0.01M-0.02M0.00M-0.01M0.00M0.00M-0.01M-0.00M0.00M-0.01M-0.00M-0.01M-0.02M
Net income details
EBT
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
Profit After TaxPAT
-0.39M-0.42M-0.57M-0.18M-0.63M-1.44M-1.10M-0.26M-0.42M-0.72M0.12M-0.55M-0.25M-0.33M-0.40M-0.43M-0.32M-0.22M
Income from Continuing OperationsIncome (Continuing)
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
Consolidated Net IncomeConsol Net Inc.
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
Income towards Parent CompanyParent Net Inc
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
Net Income towards Common StockholdersNet Income
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M
Additional items
EPS (Basic)
-0.04-0.03-0.05-0.01-0.04-0.09-0.08-0.02-0.03-0.040.01-0.03-0.01-0.02-0.02-0.02-0.01
EPS (Diluted)
-0.04-0.03-0.05-0.01-0.04-0.09-0.08-0.02-0.03-0.040.01-0.03-0.01-0.02-0.02-0.02-0.01
Shares Outstanding
10.81M12.13M11.17M13.04M13.65M15.06M14.34M15.96M16.11M16.44M16.72M18.62M18.68M18.70M18.67M19.63M19.63M19.63M19.55M20.18M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
10.81M12.13M11.17M13.04M13.65M15.06M14.34M15.96M16.11M16.44M16.72M18.62M18.68M18.70M18.67M19.63M19.63M19.63M19.55M20.18M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
12.05M12.14M12.97M13.29M14.23M15.48M15.62M16.00M16.37M18.10M18.50M18.66M18.70M18.70M18.70M19.63M19.63M19.63M20.18M20.18M
EBITDA
-0.39M-0.42M-0.57M-0.17M-0.61M-1.43M-1.10M-0.26M-0.42M-0.73M0.13M-0.55M-0.25M-0.32M-0.39M-0.32M-0.20M